Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2012 1
2013 2
2015 4
2016 7
2017 9
2018 5
2019 8
2020 6
2021 14
2022 10
2023 21
2024 22
2025 14
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Baden LR, et al. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30. N Engl J Med. 2021. PMID: 33378609 Free PMC article. Clinical Trial.
Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% ( …
Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI …
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.
Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, Makarova N, Goyal N, Guo W, Zappe D, Desai AS; KARDIA-1 Study Group. Bakris GL, et al. JAMA. 2024 Mar 5;331(9):740-749. doi: 10.1001/jama.2024.0728. JAMA. 2024. PMID: 38363577 Free PMC article.

LSM differences vs placebo in change from baseline to month 3 were -14.1 mm Hg (95% CI, -19.2 to -9.0; P < .001) with zilebesiran, 150 mg, once every 6 months; -16.7 mm Hg (95% CI, -21.2 to -12.3; P < .001) with zilebesiran, 300 mg, once every 3 months or ever

…

LSM differences vs placebo in change from baseline to month 3 were -14.1 mm Hg (95% CI, -19.2 to -9.0; P < .001) with zilebesiran,

…
Trigonelline is an NAD+ precursor that improves muscle function during ageing and is reduced in human sarcopenia.
Membrez M, Migliavacca E, Christen S, Yaku K, Trieu J, Lee AK, Morandini F, Giner MP, Stiner J, Makarov MV, Garratt ES, Vasiloglou MF, Chanvillard L, Dalbram E, Ehrlich AM, Sanchez-Garcia JL, Canto C, Karagounis LG, Treebak JT, Migaud ME, Heshmat R, Razi F, Karnani N, Ostovar A, Farzadfar F, Tay SKH, Sanders MJ, Lillycrop KA, Godfrey KM, Nakagawa T, Moco S, Koopman R, Lynch GS, Sorrentino V, Feige JN. Membrez M, et al. Nat Metab. 2024 Mar;6(3):433-447. doi: 10.1038/s42255-024-00997-x. Epub 2024 Mar 19. Nat Metab. 2024. PMID: 38504132 Free PMC article.
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.
Desai AS, Karns AD, Badariene J, Aswad A, Neutel JM, Kazi F, Park W, Stiglitz D, Makarova N, Havasi A, Zappe DH, Saxena M; KARDIA-2 Study Group. Desai AS, et al. JAMA. 2025 Jul 1;334(1):46-55. doi: 10.1001/jama.2025.6681. JAMA. 2025. PMID: 40434761 Free PMC article. Clinical Trial.

The least-squares mean difference between zilebesiran and placebo in change from baseline to 3 months in 24-hour mean ambulatory SBP was -12.1 mm Hg (95% CI, -16.5 to -7.6; P < .001) for indapamide, -9.7 mm Hg (95% CI, -12.9 to -6.6; P < .001) for amlodipine,

…
The least-squares mean difference between zilebesiran and placebo in change from baseline to 3 months in 24-hour mean ambulatory SBP was -12 …
Computation in bacterial communities.
Ostovar G, Naughton KL, Boedicker JQ. Ostovar G, et al. Phys Biol. 2020 Oct 9;17(6):061002. doi: 10.1088/1478-3975/abb257. Phys Biol. 2020. PMID: 33035198 Review.
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301 Study Group. Dunkle LM, et al. N Engl J Med. 2022 Feb 10;386(6):531-543. doi: 10.1056/NEJMoa2116185. Epub 2021 Dec 15. N Engl J Med. 2022. PMID: 34910859 Free PMC article. Clinical Trial.
Over a period of 3 months, 77 cases of Covid-19 were noted - 14 among vaccine recipients and 63 among placebo recipients (vaccine efficacy, 90.4%; 95% confidence interval [CI], 82.9 to 94.6; P<0.001). Ten moderate and 4 severe cases occurred, all in placebo recipients, …
Over a period of 3 months, 77 cases of Covid-19 were noted - 14 among vaccine recipients and 63 among placebo recipients (vaccine efficacy, …
Mechanism for plasmon-generated solvated electrons.
Al-Zubeidi A, Ostovar B, Carlin CC, Li BC, Lee SA, Chiang WY, Gross N, Dutta S, Misiura A, Searles EK, Chakraborty A, Roberts ST, Dionne JA, Rossky PJ, Landes CF, Link S. Al-Zubeidi A, et al. Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2217035120. doi: 10.1073/pnas.2217035120. Epub 2023 Jan 10. Proc Natl Acad Sci U S A. 2023. PMID: 36626548 Free PMC article.
The association between gut microbiota and metabolic dysfunction-associated steatotic liver disease (MASLD): a case-control study.
Rohani P, Shojaie S, Nikparast A, Shaygantabar M, Marvasti FE, Asghari G, Ejtahed HS, Sohouli MH, Hasani-Ranjbar S, Siadat SD, Larijani B, Ostovar A. Rohani P, et al. BMC Pediatr. 2025 Oct 9;25(1):796. doi: 10.1186/s12887-025-06144-z. BMC Pediatr. 2025. PMID: 41068660 Free PMC article.
Based on the analysis in the crude model and with adjustments for age, sex, and BMI, an inverse correlation was detected between the number of Coprococcus bacteria and the odds of MASLD(OR = 0.87, 95% CI: 0.77-0.98; P trend = 0.032 and OR = 0.81, 95% CI: 0.67-0.99; P …
Based on the analysis in the crude model and with adjustments for age, sex, and BMI, an inverse correlation was detected between the number …
How Can We Best Measure Frailty in Cardiosurgical Patients?
Laux ML, Braun C, Schröter F, Weber D, Moldasheva A, Grune T, Ostovar R, Hartrumpf M, Albes JM. Laux ML, et al. J Clin Med. 2023 Apr 20;12(8):3010. doi: 10.3390/jcm12083010. J Clin Med. 2023. PMID: 37109346 Free PMC article.

In-hospital stay correlated with timed up-and-go (TUG) (TAU: 0.094, p = 0.037), Barthel index (TAU-0.114, p = 0.032), hand grip strength (TAU-0.173, p < 0.001), and EuroSCORE II (TAU 0.119, p = 0.008). ICU/IMC stay duration correlated with TUG (TAU

…
In-hospital stay correlated with timed up-and-go (TUG) (TAU: 0.094, p = 0.037), Barthel index (TAU-0.114, p = 0.032), hand gri …
120 results